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Abstract: Persistent low-grade inflammation and premature ageing are hallmarks of the uremic
phenotype and contribute to impaired health status, reduced quality of life, and premature mortality
in chronic kidney disease (CKD). Because there is a huge global burden of disease due to CKD,
treatment strategies targeting inflammation and premature ageing in CKD are of particular interest.
Several distinct features of the uremic phenotype may represent potential treatment options to
attenuate the risk of progression and poor outcome in CKD. The nuclear factor erythroid 2-related
factor 2 (NRF2)–kelch-like erythroid cell-derived protein with CNC homology [ECH]-associated
protein 1 (KEAP1) signaling pathway, the endocrine phosphate-fibroblast growth factor-23–klotho axis,
increased cellular senescence, and impaired mitochondrial biogenesis are currently the most promising
candidates, and different pharmaceutical compounds are already under evaluation. If studies in
humans show beneficial effects, carefully phenotyped patients with CKD can benefit from them.
Keywords: ageing; chronic kidney disease; end-stage kidney disease; inflammation; premature ageing;
senescence; uremic toxins
Key Contribution: We summarize the current literature on uremic inflammation and premature
ageing in Chronic Kidney Disease and discuss potential treatment strategies.
1. Introduction—CKD, Inflammation, and Premature Ageing
Chronic kidney disease (CKD) is a major global health burden that contributes to increased
morbidity and mortality in affected patients [1]. Inflammation is a key risk factor for CKD progression [2],
and recent data from the CANTOS trial suggest that anti-inflammatory treatment in patients with
CKD reduces major adverse cardiovascular events [3]. Compared to the general population, patients
with CKD also have a highly accelerated ageing process that is characterized by vascular disease;
a persistent, low-grade inflammatory status; sarcopenia; and other maladies [4]. Both inflammation
and ageing (i.e., “inflammageing”) are established risk factors for mortality in a cluster of “burden of
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lifestyle diseases”, such as CKD [5], which has been recognized as one of the prototype diseases for
premature ageing [6]. Persistent inflammation, premature ageing, and CKD share common regulatory
patterns of distinct biological pathways. For instance, the transcription factor nuclear factor erythroid
2-related factor 2 (NRF2) is downregulated in all three conditions [7–9]. Thus, both inflammation and
premature ageing are major contributing factors to health status and outcome in patients with CKD.
The aim of this review is to summarize the clinical phenotypes of inflammation and premature
ageing in CKD. We also summarize the relationship between these two phenotypes. Furthermore, we
provide an overview of novel factors contributing to the uremic phenotype, and we describe potential
novel targets for the systemic treatment of these interrelated disorders.
2. Inflammation in CKD
2.1. Uremic Inflammation
An impaired renal function leads to the accumulation of nitrogenous substances in the blood
that would normally be excreted in the urine. At progressively increasing concentration, these
substances exert toxic effects, which eventually become apparent as symptoms of uremia. The altering
effects of the uremic milieu on the immune system has been described as uremic inflammation [10,11],
and include mechanisms of both immunoactivation and immunosuppression. Uremic inflammation
resembles the premature ageing phenotype in many ways. On the one hand, it is characterized by an
abnormal activation of the innate immune system, especially monocytes [6,12]. This immunoactivation
contributes to systemic inflammation via increased synthesis of pro-inflammatory cytokines, such as
interleukin (IL)-1, IL-6, and tumor necrosis factor (TNF) [12], and is similar to the chronic low-grade
state of systemic inflammation that is associated with an ageing immune system and has been coined
“inflammageing” [13]. Furthermore, inflammation is also a major component of other diseases that
are independent risk factors for CKD, such as obesity [14]. Importantly, an increased synthesis of
pro-inflammatory cytokines and chemokines by senescent cells is one of the main features of cellular
senescence [15,16], and has been coined senescence-associated secretory phenotype (SASP). The SASP
suggests a further bi-directional link between inflammation and ageing in CKD. On the other hand,
a downregulation and reduced function of the adaptive immune system, particularly of T and B
lymphocytes, during uremic inflammation parallels “immunosenescence” in the premature ageing
phenotype [6,10,12].
The causes of uremic inflammation are multifactorial. Exogenous factors, such as catheterization,
exposition to microbial contaminants, or biocompatibility issues during dialysis treatment [10] may play
an obvious role in the activation of the immune system and are avoidable using good clinical practice.
Possible exposure to bacterial endotoxin, which activates the immune system and contributes to systemic
inflammation, can furthermore result from comorbidities, such as gingivitis and periodontitis [17].
Patients with CKD may also show signs of intestinal dysbiosis and increased gut permeability [10],
which lead to the presence of bacterial DNA and elevated endotoxin levels, as well as elevated plasma
levels of the macrophage-derived cluster of differentiation (CD)14 [10], a co-receptor in the recognition
of bacterial endotoxin [18].
Conversely, endogenous factors that provoke uremic inflammation in CKD are linked to metabolic
deviations from normal physiology and can be categorized as (i) changes in the mineral metabolism,
especially in the levels of phosphate and sodium concentrations; (ii) regulation of oxidative stress;
and (iii) increased nonenzymatic glycation. However, these categories are interconnected and may
influence each other.
The endocrine fibroblast growth factor-23 (FGF-23)–klotho pathway (Figures 1 and 2) is important
for the resorption of phosphate in the kidney and is dysregulated in CKD. Decreased renal clearance
produces a relative overload of inorganic phosphate (Pi), which results in hyperphosphatemia and
contributes to systemic inflammation and vascular calcification/early vascular ageing (EVA) [19]
(Figure 2). Hyperphosphatemia promotes endothelial dysfunction and trans-differentiation of vascular
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smooth muscle cells (VSMC) into osteoblast-like cells [20]. In bovine aortic smooth muscle cells,
high Pi promotes an osteogenic phenotype via an inflammatory mechanism involving nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-κB) signaling, which increases the generation
of reactive oxygen species (ROS). This phenotype can be prevented with the Pi binder lanthanum
carbonate [21]. Similarly, another Pi binder, sevelamer, increases levels of fetuin A, an inhibitor of
extracellular matrix mineralization, in patients with CKD [22]. As a negative acute phase protein,
low levels of fetuin A indicate systemic inflammation and may shorten telomeres in leukocytes [23].
Furthermore, high Pi induces the expression of the pro-inflammatory transcription factor NF-κB in
human aortic VSMC [24].
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Figure 1. The phosphate-fibroblast growth factor-23 (FGF-23)–klotho endocrine axis. Main effectors of
phosphate homeostasis with potential effects on ageing components (simplified overview). Phosphate
(Pi) is taken u by the n estine and accumulates in the circulation of patients with advanced chronic
kidney disease (CKD). In the circulation, fetuin A (blue circles)-bound calcium Pi in calciprotein
particles (CPP) prevents precipitation of calcium Pi in the circulation. Increased Pi is further regulated
by parathyroid hormone (PTH) secreted from the four parathyroid glands (orange circles) at the back
of thyr id gland by increasing intestinal Pi resorption but also inducing phosphaturia. The 1,25(OH)2
vitamin D3 metabolite is activated in the kidneys and increases intestinal Pi resorption. Furthermore,
bone-secreted fibroblast growth factor-23 (FGF-23) also exerts phosphaturic effects through its mandatory
co-receptor klotho in the kidneys.
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Figure 2. The phosphate-FGF-23–klotho endocrine axis and premature ageing in CKD. Association
of the different effectors of the phosphate homeostasis with ageing components (light blue arrows:
inducers; red arrows: inhibitors). In advanced CKD, calciprotein particles (CPP) can induce early
vascular ageing (EVA) and inflammation. However, contradictory findings also suggest a beneficial
role of CPP on EVA. Circulating phosphate (Pi) promotes EVA, cellular senescence, and oxidative stress
by different mechanisms. Vitamin D inhibits inflammation and oxidative stress directly or indirectly.
The anti-ageing-associated klotho counteracts EVA, cellular senescence, inflammation, and oxidative
stress. Data for fibroblast growth factor-23 (FGF-23) are limited and further studies need to investigate
whether FGF-23 directly induces different ageing components or whether the clinical associations to
ageing are mediated by other factors, such as Pi.
Although Pi levels increase in the circulation of CKD patients, sodium accumulates in the tissue
under uremic conditions and may l ad to chronic systemic i flammation via activatio of the p38
mitogen-activated pr tein kinase (MAPK) pathway and induction of IL-17-producing CD4+ T helper
cell [6,25].
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The transcription factor NRF2 plays an important and ancient role in the anti-oxidant response.
Following oxidative stress, NRF2 dissociates from its repressor kelch-like erythroid cell-derived protein
with CNC homology [ECH]-associated protein 1 (KEAP1) in the cytosol and subsequently translocates
to the nucleus, where it binds to the anti-oxidant response element of numerous promoter regions of over
300 genes encoding anti-oxidant and detoxifying molecules [26]. In peripheral blood mononuclear cells
from CKD patients, NRF2 is down-regulated, whereas NF-κB is in turn up-regulated [27]. NF-κB plays
a key role in regulating the inflammatory response and is stimulated by ROS [10]. This suggests that
uremia induces an impaired NRF2 system in CKD and hemodialysis (HD) patients, which contributes
to the pathogenesis of oxidative stress and inflammation [27]. Importantly, increased oxidative stress
and its sequalae are major contributors to premature atherosclerosis and calcification [28], resulting in
increased cardiovascular (CV) morbidity and mortality in CKD [29,30]. Retained uremic toxins may
further both become substrates for oxidative injury and increase the burden of oxidative stress [29,30].
Advanced glycation end-products (AGE) are formed from reducing sugars and biomolecules such
as proteins, lipids, and nucleic acids by a sequence of nonenzymatic glycation reactions, collectively
known as the Maillard reaction [26,31]. Exogenous sources of AGE originate from diet [32] and
tobacco smoking [33]. Endogenously, AGE formation is promoted by hyperglycemia, but also by
high levels of oxidative stress [26]. In fact, oxidative stress and AGE formation mutually stimulate
each other [34]. AGE increase the levels of ROS via activation of Nicotinamide adenine dinucleotide
phosphate (NADPH) oxidase through interaction with the advanced glycation end product-specific
receptor (RAGE), as well as through receptor-independent pathways, whereas ROS decrease the
levels of glyoxalase I (Glo-1), an enzyme that detoxifies AGE precursor molecules [26]. In CKD, AGE
accumulate as a result from both a decreased renal clearance and increased formation [26]. AGE–RAGE
interaction activates the NF-κB pathway and thus perpetuates uremic inflammation via release of
pro-inflammatory cytokines, such as IL-1, IL-6, and TNF [35].
2.2. Consequences of Inflammation on Premature Ageing in CKD
Persistent uremic inflammation directly promotes premature ageing and further increases
inflammatory effects through a vicious circle. For instance, NF-κB promotes cellular senescence
and accelerated ageing but it is also activated in senescent cells [36–38]. In more detail, senescent cells
promote inflammation through the transcription factor GATA4, which increases NF-κB to initiate the
SASP [39]. Furthermore, cell replication is amplified in acute and chronic inflammation, resulting in
increased telomere attrition, which is directly linked to cellular ageing [40]. Importantly, the association
between telomere length and inflammation also seems to be reciprocally. Thus, mice deficient in the
telomerase genes telomerase RNA component (TERC) and telomerase reverse transcriptase (TERT) show
a higher amount of mRNA expression of various pro-inflammatory cytokines [41]. In a cross-sectional
study, the negative association of leukocyte telomere length with circulating inflammatory markers
was also confirmed in prevalent HD patients [23]. Moreover, increased oxidative stress in CKD and
adverse lifestyle factors (e.g., smoking and diet), as well as psychological stress, may further promote
telomere shortening through inflammation [40].
3. Premature Ageing in CKD
Because the kidneys are involved in the regulation of many systemic processes, patients with
CKD are at a high risk to develop multiple systemic complications, including rheologic, metabolic,
immunologic, CV, and other disturbances [42]. Importantly, several of these complications show
similarities with the ageing process, such as CV diseases (CVD), sarcopenia, bone disease, as well
as frailty [43,44], cognitive dysfunction [44], immune deficiency [12], and finally mortality [1].
Thus, patients with CKD appear to have a highly accelerated ageing process as compared to healthy
subjects or non-CKD patients. We present possible causes for the premature ageing process in CKD,
focusing on uremic toxins including AGE, the endocrine phosphate-FGF-23–klotho axis, as well as
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NRF2 as a master regulator of mitochondrial dysfunction/oxidative stress. Importantly, all pathways
are linked to hallmarks of the ageing process [45].
3.1. Uremic Toxins and Premature Ageing in CKD
When renal function declines during the progression of CKD, distinct organic compounds
accumulate [46], and signs and symptoms of uremia occur. The European Uremic Toxins (EUTox)
Work Group has provided a comprehensive overview of circulating solutes in CKD [47] describing
a large number of uremic toxins with significantly differing circulating levels in end stage kidney
disease (ESKD), which can be sorted into three groups: (1) free water-soluble low-molecular-weight
solutes, (2) protein-bound solutes, and (3) middle molecules [47]. For a variety of these uremic
toxins, associations with the ageing process have been described. Thus, the protein-bound uremic
toxins indoxyl sulfate and p-cresyl sulfate induce oxidative stress by different mechanisms [48].
Using an in vitro approach, indoxyl sulfate attenuates mitochondrial activity in human renal proximal
tubule epithelial cells [49] and human umbilical vein endothelial cells [50], thereby affecting the
cellular metabolic capacity. Furthermore, indoxyl sulfate induces markers of senescence, including
senescence-associated beta-galactosidase (SA-β-gal), through oxidative stress [51]. Indoxyl sulfate and
p-cresyl sulfate also increased mitochondrial autophagy (“mitophagy”) [52]. Although autophagy in
general has been suggested as a compensatory and pro-survival mechanism [53], it could also have
adverse effects when mitochondrial mass decreased at a level beyond cellular compensation [52].
Thus, mitochondrial dysfunction is one of the key mechanisms linking uremic toxins with hallmarks of
the ageing process [45] through increased oxidative stress [54]. It should be noted that indoxyl sulfate
dose-dependently decreases protein levels of klotho in human aortic VSMC in vitro by inducing DNA
methylation of the klotho-coding Kl gene [55]. In accordance, patients with ESKD have increased
promoter hypermethylation of the Kl gene [55]. Conversely, the inhibition of uremic toxins should
have beneficial effects on ageing markers. As an example drug, the oral sorbent AST-120 adsorbs
uremic toxins and their precursors within the gastrointestinal tract [56]. AST-120 dose-dependently
decreases circulating indoxyl sulfate [56] and was, therefore, tested in several clinical trials [56]. Results
of these trials were heterogenous depending on the prespecified primary endpoints, follow-up period,
as well as baseline characteristics of the included subjects. In conclusion, there was no effect of adding
AST-120 to standard therapy in patients with moderate to severe CKD on a primary composite renal
end point in the EPPIC trials [57]. It should be noted, however, that on the basis of the results of a
subgroup analysis in the EPPIC trials, AST-120 delayed the time of reaching the primary renal end
point in patients from the United States [58].
AGE are another group of uremic toxins that accumulate in CKD [26]. Besides the well-known
associations of AGE levels and CVD (mostly investigated in patients with diabetes mellitus) [59,60],
AGE and AGE-detoxifying enzymes including Glo-1 also have direct effects on ageing processes.
Thus, the AGE–RAGE axis induces renal cytosolic oxidative stress and mitochondrial dysfunction,
as well as inflammation [26,61]. The AGE–RAGE axis further promotes premature senescence in
proximal tubular epithelial cells via endoplasmatic reticulum stress and p21 activation in an in vivo
and in vitro approach [62]. Moreover, AGE-induced endoplasmatic reticulum stress also increases
p16 protein expression in tubular epithelial cells in vitro in a dose- and time-dependent manner
through the activating transcription factor 4 [63]. Conversely, reduced renal senescence in tubule iss
observed in rodents with a transgenic overexpression of the AGE-detoxifying enzyme Glo-1 in vivo
and in vitro [54]. More recently, AGE have been shown to induce renal senescence in mesangial cells
via the RAGE/Signal transducer and activator of transcription 5 (STAT5) pathway and inhibiting
autophagy [64].
Taken together, uremic toxins, including AGE, have distinct and adverse effects on the pro- and
anti-oxidative milieu, mitochondrial function, inflammation, and finally cellular senescence; all of
which are hallmarks of the ageing process [45] (Figure 3).
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Figure 3. Mechanisms by which uremic toxins and advanced glycation end products (AGE) induce
pro-ageing effects. Both uremic toxins and AGE have adverse effects on mitochondrial function
including formation of reactive oxygen species (ROS) but also structural disturbances. They impair
anti-ageing defenses of the organism, and induce inflammation, as well as cellular senescence. All effects
result in an adverse, pro-ageing milieu caused by uremic toxins and AGE. Light blue arro s: inducers;
re arrows: inhibitors. ATF4: activating transcription factor 4, ROS: reactive oxygen speci , SA-β-gal:
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3.2. e docrine Phosphate-FGF-23–Klotho Axis and Premature Ageing in CKD
r negative association of serum Pi levels with life span has been reported in mammals [8].
Phos ate o eostasis is reg lated by a distinct endocrine network involving vitamin D, parathyroid
hormone (PTH), klotho, and FGF-23 (Figure 1). In more detail, Pi originating from dietary intake is absorbed
bythesmall intestinebyanactive transcellular transportoraparacellularpathway[65]. Inhypophosphatemia,
either normal or increased levels of the active metabolite 1,25(OH)2 vitamin D3 are observed in humans [66],
and 1,25(OH)2 vitamin D3 increases the rate of intestinal Pi resorption [67]. Furthermore, the parathyroid
glands are affected by elevated serum Pi levels and release PTH, which enhances urinary Pi excretion by
PTH-induced removal of the renal sodium Pi cotransporters from the apical membrane [68]. Bone-derived
FGF-23 limits hyperphosphatemia by induc g phosphaturia and suppressing vitami D secretion [69].
FGF-23 signals through endocrine FGF receptor complexes [70] and also associates with distinct metabolic
components [71]. FGF-23 requires klotho protein as a co-receptor [70]. The full length klotho protein,
which is predominantly expressed in the proximal and distal tubules of the kidneys [72], is cleaved and
circulates as a soluble klotho fragment serving as a surrogate marker of renal klotho expression [70].
In the circulation, calciprotein particles (CPP) “capture” calcium (Ca) and Pi with the help of the
adipokine fetuin A and prevent the precipitation of Ca-Pi [70,73].
Phosphate induces EVA via different mechanisms, and higher serum Pi concentrations, even if
they are within the normal range, have been found to be associated with microvascular dysfunction in
a Dutch, population-based cohort study [74] (Figure 2). In human aortic VSMC, Pi treatment arrests
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the cell cycle [75], mediating cellular senescence. In vitro, Pi further induces vascular calcification
and production of ROS [76]. Mediated by Ca-Pi crystals and a disturbed microRNA homeostasis,
Pi has additional indirect and negative effects on EVA [77]. Importantly, these in vitro data on EVA are
supported by a Scottish general population study showing that Pi is linked to markers of biological
age, that is, reduced telomere length, DNA methylation content, and chronological age [78].
Adverse effects of Pi on EVA are at least in part mediated by the Wnt/beta-catenin pathway [79,80].
Thus, high Pi activates the Wnt/beta-catenin pathway in VSMC in vitro, promoting VSMC calcification
and osteogenic transition [79]. Conversely, shRNA-mediated knockdown of beta-catenin in CKD rats
on a high-phosphate diet reduced vascular calcification [79]. Interestingly, klotho is an inhibitor of
the Wnt/beta-catenin pathway [70], ameliorating high Pi-induced VSMC calcification [81], as well as
inhibiting osteogenic transition of these cells [82,83]. Taken together, Pi induces EVA at least in part by
the Wnt/beta-catenin pathway, and different treatment approaches potentially mitigate the adverse
effects of Pi on EVA, including klotho.
Besides preventing the precipitation of Ca-Pi (Figure 2), CPP can induce pro-inflammatory effects
in VSMC in vitro [84], further linking inflammation and EVA in CKD. Furthermore, CPP differ between
healthy subjects and patients with ESKD and can, therefore, promote widespread calcification in
CKD [85].
Because of the above-mentioned evidence of a direct association between Pi and premature ageing
in CKD, non-pharmaceutical prevention strategies could potentially reduce the burden of disease,
including changes in lifestyle. However, there is a lack of studies linking diets that lower Pi levels to
a beneficial clinical outcome [86,87]. Furthermore, whereas low-Pi diets can reduce FGF-23 levels in
CKD [88], there was no dose-dependent effect of Pi lowering on FGF-23 reduction when low- and very
low phosphate diets were compared in a recent short-term, randomized, crossover trial in 35 ESKD
patients [89]. Therefore, non-pharmacological lifestyle-changing prevention strategies might provide a
benefit on components of the ageing process, but randomized controlled trials are needed to prove
these associations.
Vitamin D has also been linked to distinct components of the ageing process (Figure 2).
The negative acute phase reactant vitamin D [90] mitigates oxidative stress at least in part through
increased expression of anti-oxidant regulators, including NRF2 and klotho [91–93]. Thus, calcitriol
increased renal and circulating klotho expression, whereas it reduced markers of oxidative stress in
uninephrectomized, spontaneously hypertensive rats [94]. These data have been confirmed in a recent
randomized controlled trial showing increased circulating klotho and total antioxidant capacity after 12
weeks of cholecalciferol treatment compared to the placebo group [95]. Human ex vivo studies indicate
that vitamin D exerts anti-inflammatory effects on uremic lymphocytes under renal replacement
therapy (RRT) [96]. Meta-analyses demonstrating reduced circulating markers of inflammation in
mostly non-CKD subjects on vitamin D supplementation [97,98], further supporting a significant role
of vitamin D on the hallmarks of ageing. However, these associations were not seen in CKD patients
on vitamin D supplementation [99]. Furthermore, two systematic reviews and meta-analyses did not
find strong evidence for a beneficial effect of vitamin D supplementation on arterial stiffness [100]
and endothelial function [101], two major components of EVA. Thus, future studies need to validate
whether vitamin D has direct effects on premature ageing in CKD or whether its effects are mediated
by NRF2, klotho, and others.
FGF-23 has been associated with an adverse outcome in CKD in large studies [102]. However, only
a few experimental studies have investigated causal effects of FGF-23 on inflammation and premature
ageing as hallmarks in the pathogenesis of CKD and its complications. Thus, FGF-23 induces hepatic
inflammation in CKD [103]. Furthermore, some [104,105] but not all [106] studies suggest that FGF-23
might induce EVA. Taken together, data for direct FGF-23 effects on renal inflammation and premature
ageing in CKD are limited (Figure 2).
Simic et al. [107] recently showed that kidney-derived glycerol-3-phosphate in the renal vein
correlated with circulating FGF-23 levels, and they further demonstrated a novel kidney–bone axis by
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which renal glycerol-3-phosphate increases bone-secreted FGF-23. Future studies need to investigate
whether renal glycerol-3-phosphate could also be a potential target for preventing premature ageing.
With respect to premature ageing, klotho (Figure 2) is clearly the most interesting member of
this endocrine axis, as Kuro-o et al. [70] described a syndrome that resembles human ageing in
mice that have a defect in the klotho-coding kl gene. When renal function declines, klotho levels
decrease in humans and in rodents with CKD [70]. Klotho-overexpressing mice with CKD have an
increased phosphaturia, as well as an improved renal function and EVA phenotype [72]. In mice
with an ICR-derived glomerulonephritis, overexpression of the kl gene reduces blood urea nitrogen
levels, proteinuria, renal SA-β-gal activity, and the development of glomerular and tubulointerstitial
changes [108]. Mechanistically, klotho-overexpressing mice show an improved mitochondrial function,
as well as a reduced mitochondrial DNA damage and oxidative stress, in the kidneys [108].
Interestingly, both high Pi and inflammation decrease renal Kl mRNA expression in vitro [109].
Thus, 5/6 nephrectomized rats on a 0.4% phosphorus diet showed reduced renal klotho protein
expression compared to sham-operated animals [109]. Lipopolysaccharide-induced inflammation
further reduced klotho expression in all groups [109]. In vivo and ex vivo pharmacological inhibition
of NF-κB and Wnt recovered reduced klotho expression after lipopolysaccharide treatment [109]
further suggesting that inflammation and the Wnt/beta-catenin pathway are crucially involved in
the downregulation of renal klotho in CKD. The pro-fibrotic transforming growth factor (TGF)-β,
which is upregulated in CKD, is another mediator of reduced renal klotho in CKD, facilitating adverse
Wnt/beta-catenin activation in the kidney [110].
Besides these in vivo data in renal tissue, klotho exerts beneficial effects on the endothelium
including attenuation of inflammatory and adhesion molecules, as well as augmented NO
production and vasorelaxation [111]. Moreover, klotho-deficient mice show increased vascular
calcification [112,113], further supporting a beneficial role of klotho on EVA. In addition,
the above-described role of uremic toxins in reducing klotho expression further strengthens these
effects in CKD. Finally and most importantly, because overexpression of klotho in mice extends their
lifespan [70], klotho is one of the most promising anti-ageing targets in CKD.
3.3. Mitochondrial Dysfunction/Oxidative Stress and Premature Ageing in CKD
Patients with CKD show increased oxidative stress on the basis of an over-production of
ROS, as well as decreased anti-oxidant defenses [29,114]. In general, ROS are generated from the
reduction of oxygen and can induce oxidation of important macromolecules, including proteins, lipids,
carbohydrates, and DNA [29,114], thereby exerting toxic effects on mitochondria [115]. Thus, sufficient
anti-oxidative mechanisms are necessary to counteract the excessive ROS formation in cells. One of the
most interesting anti-oxidative targets interfering with ageing is the transcription factor NRF2, which
is a key regulator of anti-oxidative enzymes. When oxidative stress occurs, NRF2 translocates to the
nucleus and activates >300 distinct genes that have an anti-oxidant response element in their promoter
regions [26,116]. Mitochondrial dysfunction in CKD is associated with low NRF2 expression in human
skeletal muscle [117]. NRF2 is also negatively associated with different other age-related lifestyle
diseases [9] and rare progeroid syndromes [7]. Thus, patients with Hutchinson–Gilford progeria
syndrome (HGPS) show an impaired activity of the NRF2 pathway, and reactivation of NRF2 in ex
vivo cells of patients with HGPS can reverse ageing defects [118]. Mechanistically, NRF2 knockdown
in wildtype fibroblasts increases oxidative stress and recapitulates cellular senescence defects of
HGPS [118]. Furthermore, caveolin-induced NRF2 inhibition induces senescence in murine adipocytes
in vitro and, conversely, less inhibition of NRF2-dependent anti-oxidant signaling results in decreased
senescence, as assessed by SA-β-gal and p21Waf1/Cip1 [119]. Molecular markers of vascular senescence,
that is, p16INK4a and p21Waf1/Cip1, as well as cytokines of the SASP, are increased in NRF2-deficient mice
compared to control mice [120]. Klotho also exerts some of its beneficial effects on EVA by activating the
NRF2 pathway [121]. Furthermore, because testosterone ameliorates age-related renal fibrosis in mice
via activation of NRF2 signaling [122], the effects of sex hormones and their supplementation in CKD
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also need attention. In ESKD, reduced NRF2 expression in peripheral blood mononuclear cells has
been reported in addition to an up-regulation of pro-inflammatory NF-κB [27]. Furthermore, uremic
toxins correlate positively with NF-κB expression and negatively with NRF2 expression in peripheral
blood mononuclear cells [123]. Accordingly, rats undergoing 5/6 nephrectomy also show an impaired
activation of NRF2 in the kidneys [124]. Conversely, the NRF2 agonist bardoxolone reduces tubular
cell mitochondrial damage and improves redox balance and mitochondrial function in a CKD mouse
model [125]. Taken together, mitochondrial dysfunction and oxidative stress promote premature
ageing. Because the protective NRF2 pathway is attenuated in CKD and other burden of lifestyle
diseases associated with ageing, this offers the potential for future NRF2 agonist-based treatment.
4. Secondary Premature Ageing by CKD-Causing Diseases and CKD Treatment
As described above, many facets of CKD contribute to premature ageing. However, distinct causes
of CKD contribute to premature ageing, irrespective of renal function, and are summarized below.
4.1. Glomerular Diseases Excluding Diabetic Kidney Disease (DKD)
In contrast to other CKD causes, the incidence of IgA nephropathy (IgAN) does not increase with
age and is, therefore, higher in children and young adults as compared to elderly subjects [126,127].
In Asian cohorts of IgAN, renal biopsies show higher expressions of p16INK4 [128], p21 [129], and
reduced klotho [128] compared to controls. Furthermore, p16INK4, as well as klotho, correlated with
IgAN-related renal fibrosis [128]. Because other glomerular diseases, including focal segmental
glomerulosclerosis and minimal change disease, are also associated with an increased renal expression
of the senescence marker p16INK4A [127], glomerular diseases seem to have direct relations to premature
ageing. Patients with Fabry disease have shorter leukocyte telomere length compared to controls [130].
Thus, this rare renal disease could also serve as a model of premature ageing [131].
4.2. Polycystic Kidney Disease as a Model of Adverse Anti-Senescence
Patients with autosomal dominant polycystic kidney disease (ADPKD) often progress to CKD and
ESKD [132]. Interestingly and in contrast to most other underlying CKD causes, the senescence marker
p21Waf1/Cip1 is decreased in both human and rodent ADPKD, suggesting that an anti-senescent milieu
promotes cyst formation [127]. In accordance with this hypothesis, the cyclin-dependent kinase inhibitor
roscovitine reduces cyst formation in mice with PKD [127]. In contrast, nephronophthisis, another
cystic kidney disease, is characterized by cellular senescence [133]. Furthermore, senolytic treatment
in mice with nephronophthisis type 7 improves cystic area, inflammation, and renal fibrosis [134].
These contradictory findings indicate that senescence must be viewed as disease-specific and in the
context of a spectrum ranging from beneficial to adverse effects.
4.3. Obesity, Diabetes Mellitus, and DKD
Obesity is a major predictor contributing to type 2 diabetes (T2D), CKD, CVD, and increased
mortality [135,136]. Besides being risk factors for CKD, obesity and T2D also contribute to cellular
senescence per se [137,138]. Furthermore, the adverse effects of an increased fat mass are at least
partly related to the secretion of proteins from adipocytes into the circulation, that is, adipocytokines.
Indeed, adipocytokines associate with adverse metabolic status and the SASP [71,139]. Interestingly,
treatment of obese mice with the senolytic agents dasatinib and quercetin improves glucose tolerance,
enhances insulin sensitivity, lowers circulating inflammatory mediators, and increases levels of the
beneficial adipocytokine adiponectin [140]. Furthermore, distinct adipocytokines can also contribute
to attenuated vascular calcification in CKD, such as chemerin [141].
With respect to DKD, both humans and mice with DKD have an increased expression of senescence
markers, including SA-β-gal, p16INK4A, and p21Waf1/Cip1, in different renal cell types, and diabetic,
p21-deficient mice are protected from DKD compared to diabetic wildtype mice [127]. However,
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future studies need to validate whether hyperglycemia rather than DKD itself might cause this
pro-senescent phenotype.
4.4. CKD-/ESKD Treatment-Associated Ageing (Dialysis, Transplantation)
As the uremic milieu associates with premature ageing and senescence, one could speculate that
RRT (dialysis and renal transplantation [Rtx]) improves a prematurely aged phenotype. However,
the dialysis procedure itself exerts pro-inflammatory and pro-oxidative effects due to multiple
factors, such as bio-incompatibility of dialysis membranes or fluids, contaminated/polluted dialysis
water, intravenous iron treatment, activation of the renin–angiotensin–aldosterone system (RAAS),
and depletion of anti-oxidants [6] potentially resulting in adverse effects on ageing processes in RRT.
Ageing-associated phenotypes are also observed after Rtx. Thus, patients undergoing Rtx have an
increased risk for complications, including ischemia-reperfusion injury (IRI) and allograft rejection
during and after Rtx. These complications can result in an accelerated senescence as assessed by
p21Waf1/Cip1 and p16Ink4a, as well as telomere shortening [127]. Furthermore, transplant biopsies
show strong p16INK4a staining beyond the amount predicted by chronological age [142]. Conversely,
short-term inhibition of the senescence promoter p53 reduces IRI-induced senescence and improves
kidney outcome in mice [143]. Immunosuppressive treatment of the recipients can further result in
therapy-induced senescent cells that remain in the transplanted kidney and mediate adverse pro-ageing
signals [144]. Thus, patients receiving mycophenolate mofetil after Rtx have an increased telomere
attrition compared to azathioprine-treated patients, supporting a direct effect of immunosuppressive
treatment on ageing [145]. Taken together, RRT by either dialysis or Rtx does not arrest ageing processes,
and RRT might even accelerate the ageing phenotype.
5. Approaches for Handling of Inflammation and Premature Ageing in CKD
Inflammation and premature ageing are hallmarks in the pathogenesis of CKD and its many
complications, having highly detrimental effects on health status, quality of life, and mortality. However,
current treatment recommendations indicate that each single risk factor for CKD progression and
its complications must be treated separately and, at the final stage, RRT has to be provided [42].
This approach led to substantial improvements in reducing example, in patients with T1D, the use
of novel insulins, new glucose monitoring devices, and the widespread usage of RAAS blockers
has improved the outcome [146,147]. However, because the global burden of disease due to CKD is
increasing [148], systemic approaches for the treatment of CKD and its complications are warranted to
target the underlying hallmarks of CKD, that is, inflammation and premature ageing. Some of these
are summarized below.
5.1. NRF2–KEAP1 Signaling Pathway
Several groups have independently shown beneficial associations and effects of the NRF2 system
as a key regulator of anti-oxidative enzymes in CKD, and promote NRF2 as a multiorgan protector.
Concluding the findings discussed above, treatment of the repressed NRF2 system in CKD can
improve oxidative stress and mitochondrial function [125,149], inflammation [27,123,149], as well as
premature ageing [122], in particular EVA [120,121].
NRF2-inducing treatment options include nutritional components, exercise [150], and pharmaceutical
compounds targeting NRF2 or inhibiting the binding of NRF2 to KEAP1 [116]. Although the
above-mentioned beneficial effects of NRF2 have drawn interest to this molecular “health promoter”,
potential caveats should be acknowledged. Firstly, NRF2 has dual roles in its association with
carcinogenesis, as well as cancer progression and therapy. Thus, NRF2 activation in normal cells can
prevent cancer initiation [151]. In contrast, prolonged NRF2 activation is involved in cancer promotion,
progression, and treatment resistance [151]. Consequently, each NRF2-based approach must carefully
investigate oncogenic risk as a potential side effect. Secondly, despite promising initial results, previous
treatment approaches for patients with DKD using the NRF2 agonist bardoxolone have been stopped
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due to an excess of heart failure hospitalizations among those assigned to bardoxolone [7]. However,
because patients with risk factors for heart failure could be identified and excluded, bardoxolone is
currently being re-investigated in different clinical trials comprising patients with CKD and underlying
pathologies [116]. When patients in these studies are carefully selected, the NRF2 agonist might have
beneficial effects on several hallmarks of the uremic phenotype, such as inflammation, oxidative stress,
as well as on premature ageing. Thus, NRF2 is currently a promising and the clinically most advanced
signaling pathway for the treatment of both inflammation and premature ageing in CKD. It should be
kept in mind that it is also possible to target NRF2 by nutraceuticals, such as sulforaphane [7].
5.2. Klotho Pathway
Kidney-derived klotho is of particular interest as a potential treatment for inflammation and
premature ageing in CKD, because klotho-deficient mice and patients with CKD have similar
phenotypes, such as EVA and a pro-inflammatory status, and klotho is related to ageing in both humans
and mice [70,72]. Similar to the NRF2 system, klotho is repressed in CKD, and stimulation of klotho
can ameliorate oxidative stress and mitochondrial function [108], renal fibrosis [152], inflammation [72],
as well as premature ageing [108], including EVA [55,81–83,111–113].
Importantly, and possibly in contrast to the NRF2–KEAP1 signaling pathway, klotho is
down-regulated in several cancers and is also recognized as a potential anti-tumor therapy [153].
Therapeutic approaches to stimulate klotho expression can aim for the reactivation of endogenous
klotho or the administration of exogenous klotho [72]. Several drugs increase endogenous klotho [72].
For instance, the thiazolidinedione pioglitazone protects against renal injury in ageing by an increased
expression of klotho [72]. Furthermore, the vitamin D analog paricalcitol induces the tissue-dependent
expression of klotho in the kidneys and increases serum and urinary klotho levels in rodent CKD
models [72]. In vitro data using murine internal medulla collecting duct epithelial cells further suggest
that statins induce klotho mRNA expression [72]. Moreover, because angiotensin II and aldosterone
decrease klotho mRNA expression in vitro and in vivo [70], RAAS blockers potentially reverse the
decrease in klotho expression in rodents [70]. Recently, testosterone was positively correlated with
circulating klotho levels in both men and women, and the association sustained significance after
adjustment for cortisol and markers of renal function but not chronological age [154]. However, and in
contrast to this study, a randomized controlled trial of transdermal testosterone does not find changes
in soluble klotho levels between the verum and placebo group [155]. Finally, direct administration
of exogenous, soluble klotho has also been proven effective for increasing circulating klotho levels,
as well as protecting against acute kidney injury and CKD [72,156]. It has to be pointed out that,
except for direct klotho administration, each of the mentioned pharmacological compounds is already
approved for the use in CKD, and for some but not all of these, positive renal outcome data in humans
with CKD are available [157]. However, the relative contribution of increased klotho on the outcome
of these human studies has not been analyzed thus far. Hence, the direct effect of klotho on uremic
inflammation and premature ageing needs to be addressed. However, preliminary safety data appear
to be more attractive compared to targeting the NRF2–KEAP1 signaling pathway.
6. Conclusions
Persistent low-grade inflammation and premature ageing are hallmarks of the uremic phenotype
and contribute to impaired health status, reduced quality of life, and premature mortality. Several
potential treatment options targeting distinct features of the uremic phenotype may attenuate the risk of
progression and poor outcome. Because the burden of disease due to CKD is huge, systemic treatment
approaches targeting the underlying hallmarks of CKD, that is, inflammation and premature ageing,
are currently being investigated. The NRF2–KEAP1 signaling pathway, the endocrine klotho axis,
increased cellular senescence, and impaired mitochondrial biogenesis are currently the most promising
candidates, and different pharmaceutical compounds are already in evaluation. If randomized
controlled trials show beneficial effects, patients with distinct CKD phenotypes can benefit from them.
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